<p>Microbot Medical Inc.（纳斯达克代码：MBOT - 获取免费报告）在九月份的空头头寸出现了大幅下降。截至九月三十日，空头头寸总计为 4,540,000 股，较九月十五日的 10,630,000 股下降了 57.3%。根据平均每日交易量 4,200,000 股，目前的覆盖天数比率为 1.1 天。</p>
<p>获取 <strong>Microbot Medical</strong> 警报：</p>
<h2>对 Microbot Medical 的对冲基金看法</h2>
<ul>
<li>Intuitive Surgical 在其 52 周高点提供了买入机会</li>
</ul>
<p>大型投资者最近买入和卖出了该公司的股票。美国资本财富顾问公司在第二季度购买了 Microbot Medical 的新头寸，价值 25,000 美元。美国世纪公司在第二季度购买了 Microbot Medical 的新头寸，价值 32,000 美元。Beacon Capital Management LLC 在第二季度将其在 Microbot Medical 的头寸提高了 166.7%。Beacon Capital Management LLC 现在拥有 16,000 股该生物技术公司的股票，价值 40,000 美元，此前在上个季度又购买了 10,000 股。Virtu Financial LLC 在第一季度购买了 Microbot Medical 的新头寸，价值 42,000 美元。最后，XTX Topco Ltd 在第二季度购买了 Microbot Medical 的新头寸，价值 43,000 美元。对冲基金和其他机构投资者拥有该公司 16.30% 的股票。</p>
<h2>Microbot Medical 价格表现</h2>
<p>MBOT 股票在周五开盘价为 2.76 美元。该公司的 50 日移动平均价格为 3.38 美元，200 日移动平均价格为 2.79 美元。Microbot Medical 的 12 个月低点为 0.89 美元，12 个月高点为 4.67 美元。该公司的市值为 1.8536 亿美元，市盈率为-4.76，贝塔值为 1.25。</p>
<ul>
<li>Microbot Medical 因其血管内手术机器人股价飙升 150%</li>
</ul>
<p>Microbot Medical（纳斯达克代码：MBOT - 获取免费报告）最后一次公布季度财报是在 8 月 12 日（星期二）。该生物技术公司报告的季度每股收益为（0.10 美元），低于分析师一致预期的（0.08 美元）2 美分。整体来看，分析师预计 Microbot Medical 在当前年度的每股收益为-0.71 美元。</p>
<h2>分析师评级变动</h2>
<p>几家券商最近对 MBOT 进行了评估。HC Wainwright 在周三的研究报告中重申了 “买入” 评级，并设定了 12.00 美元的目标价。华尔街 Zen 在 10 月 3 日（星期五）的研究报告中将 Microbot Medical 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了 Microbot Medical 的 “卖出（d-）” 评级。最后，Zacks Research 在 8 月 21 日（星期四）的研究报告中将 Microbot Medical 的股票评级从 “强力买入” 下调至 “持有”。一位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价为 12.00 美元。</p>
<p><strong>阅读我们关于 Microbot Medical 的最新报告</strong></p>
<h2>关于 Microbot Medical</h2>
<p>（获取免费报告）</p>
<p>Microbot Medical Inc 是一家临床前医疗设备公司，专注于针对微创手术领域的机器人内腔手术设备的研究、设计和开发。该公司提供 LIBERTY，一种血管内机器人手术系统，允许医生在导管实验室外进行导管基础程序，避免辐射暴露、身体负担和交叉污染的风险，适用于心血管、外周和神经血管领域。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票比 Microbot Medical 更好</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>强生的并购策略才是投资者真正关注的故事</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌吗？</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>对冲基金对美元的态度转变——这三只股票的买入信号？</li>
</ul>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Microbot Medical 吗？</h2>
<p>在考虑 Microbot Medical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Microbot Medical 并不在名单上。</p>
<p>虽然 Microbot Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得买入。</p>
<p>查看这五只股票</p>

MBOT

<p>Microbot Medical Inc.（纳斯达克代码：MBOT）在空头头寸方面经历了显著下降，截至 9 月 30 日，空头头寸从 10,630,000 股下降至 4,540,000 股，降幅为 57.3%。目前的空头头寸比率为 1.1 天，基于平均每日交易量为 4,200,000 股。该股票开盘价为 2.76 美元，市值为 1.8536 亿美元。分析师的评级意见不一，普遍评级为 “持有”，平均目标价为 12.00 美元。该公司专注于开发用于微创手术的机器人内腔手术设备</p>

<p>Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) was the target of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 4,540,000 shares, a decline of 57.3% from the September 15th total of 10,630,000 shares. Based on an average daily trading volume, of 4,200,000 shares, the days-to-cover ratio is presently 1.1 days. Based on an average daily trading volume, of 4,200,000 shares, the days-to-cover ratio is presently 1.1 days.</p>
<div class="lb-trans"><p>Microbot Medical Inc.（纳斯达克代码：MBOT - 获取免费报告）在九月份的空头头寸出现了大幅下降。截至九月三十日，空头头寸总计为 4,540,000 股，较九月十五日的 10,630,000 股下降了 57.3%。根据平均每日交易量 4,200,000 股，目前的覆盖天数比率为 1.1 天。</p>
</div><p>Get <strong>Microbot Medical</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Microbot Medical</strong> 警报：</p>
</div><h2>Hedge Funds Weigh In On Microbot Medical</h2>
<div class="lb-trans"><h2>对 Microbot Medical 的对冲基金看法</h2>
</div><ul>
<li>Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs</li>
</ul>
<div class="lb-trans"><ul>
<li>Intuitive Surgical 在其 52 周高点提供了买入机会</li>
</ul>
</div><p>Large investors have recently bought and sold shares of the company. U.S. Capital Wealth Advisors LLC purchased a new position in Microbot Medical during the 2nd quarter worth $25,000. American Century Companies Inc. purchased a new position in Microbot Medical during the 2nd quarter worth $32,000. Beacon Capital Management LLC raised its position in Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock worth $40,000 after buying an additional 10,000 shares during the last quarter. Virtu Financial LLC purchased a new position in Microbot Medical during the 1st quarter worth $42,000. Finally, XTX Topco Ltd purchased a new position in Microbot Medical during the 2nd quarter worth $43,000. Hedge funds and other institutional investors own 16.30% of the company's stock.</p>
<div class="lb-trans"><p>大型投资者最近买入和卖出了该公司的股票。美国资本财富顾问公司在第二季度购买了 Microbot Medical 的新头寸，价值 25,000 美元。美国世纪公司在第二季度购买了 Microbot Medical 的新头寸，价值 32,000 美元。Beacon Capital Management LLC 在第二季度将其在 Microbot Medical 的头寸提高了 166.7%。Beacon Capital Management LLC 现在拥有 16,000 股该生物技术公司的股票，价值 40,000 美元，此前在上个季度又购买了 10,000 股。Virtu Financial LLC 在第一季度购买了 Microbot Medical 的新头寸，价值 42,000 美元。最后，XTX Topco Ltd 在第二季度购买了 Microbot Medical 的新头寸，价值 43,000 美元。对冲基金和其他机构投资者拥有该公司 16.30% 的股票。</p>
</div><h2>Microbot Medical Price Performance</h2>
<div class="lb-trans"><h2>Microbot Medical 价格表现</h2>
</div><p>MBOT stock opened at $2.76 on Friday. The company has a fifty day moving average price of $3.38 and a 200 day moving average price of $2.79. Microbot Medical has a 12 month low of $0.89 and a 12 month high of $4.67. The company has a market cap of $185.36 million, a price-to-earnings ratio of -4.76 and a beta of 1.25.</p>
<div class="lb-trans"><p>MBOT 股票在周五开盘价为 2.76 美元。该公司的 50 日移动平均价格为 3.38 美元，200 日移动平均价格为 2.79 美元。Microbot Medical 的 12 个月低点为 0.89 美元，12 个月高点为 4.67 美元。该公司的市值为 1.8536 亿美元，市盈率为-4.76，贝塔值为 1.25。</p>
</div><ul>
<li>Microbot Medical spikes 150% on its Endovascular Surgical Robot</li>
</ul>
<div class="lb-trans"><ul>
<li>Microbot Medical 因其血管内手术机器人股价飙升 150%</li>
</ul>
</div><p>Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.10) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.02). As a group, analysts anticipate that Microbot Medical will post -0.71 earnings per share for the current year.</p>
<div class="lb-trans"><p>Microbot Medical（纳斯达克代码：MBOT - 获取免费报告）最后一次公布季度财报是在 8 月 12 日（星期二）。该生物技术公司报告的季度每股收益为（0.10 美元），低于分析师一致预期的（0.08 美元）2 美分。整体来看，分析师预计 Microbot Medical 在当前年度的每股收益为-0.71 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Several brokerages have recently weighed in on MBOT. HC Wainwright restated a &#34;buy&#34; rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Wednesday. Wall Street Zen upgraded shares of Microbot Medical from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Microbot Medical in a research report on Wednesday, October 8th. Finally, Zacks Research downgraded shares of Microbot Medical from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and an average target price of $12.00.</p>
<div class="lb-trans"><p>几家券商最近对 MBOT 进行了评估。HC Wainwright 在周三的研究报告中重申了 “买入” 评级，并设定了 12.00 美元的目标价。华尔街 Zen 在 10 月 3 日（星期五）的研究报告中将 Microbot Medical 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究报告中重申了 Microbot Medical 的 “卖出（d-）” 评级。最后，Zacks Research 在 8 月 21 日（星期四）的研究报告中将 Microbot Medical 的股票评级从 “强力买入” 下调至 “持有”。一位研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “持有”，平均目标价为 12.00 美元。</p>
</div><p><strong>Read Our Latest Report on Microbot Medical</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Microbot Medical 的最新报告</strong></p>
</div><h2>About Microbot Medical</h2>
<div class="lb-trans"><h2>关于 Microbot Medical</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.</p>
<div class="lb-trans"><p>Microbot Medical Inc 是一家临床前医疗设备公司，专注于针对微创手术领域的机器人内腔手术设备的研究、设计和开发。该公司提供 LIBERTY，一种血管内机器人手术系统，允许医生在导管实验室外进行导管基础程序，避免辐射暴露、身体负担和交叉污染的风险，适用于心血管、外周和神经血管领域。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Microbot Medical</li>
<li>5 Top Rated Dividend Stocks to Consider</li>
<li>Johnson &amp; Johnson's M&amp;A Strategy Is the Real Story for Investors</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Tesla: Some Analysts Are Calling for A 30% Drop—Time to Panic?</li>
<li>Most Volatile Stocks, What Investors Need to Know</li>
<li>Hedge Funds Flip on the Dollar—A Buy Signal for These 3 Stocks?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Microbot Medical 更好</li>
<li>5 只值得考虑的高评级分红股票</li>
<li>强生的并购策略才是投资者真正关注的故事</li>
<li>为什么这些公司被认为是蓝筹股？</li>
<li>特斯拉：一些分析师预测将下跌 30%——该恐慌吗？</li>
<li>最具波动性的股票，投资者需要知道的事项</li>
<li>对冲基金对美元的态度转变——这三只股票的买入信号？</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Microbot Medical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Microbot Medical 吗？</h2>
</div><p>Before you consider Microbot Medical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Microbot Medical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Microbot Medical 并不在名单上。</p>
</div><p>While Microbot Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Microbot Medical 目前在分析师中获得了持有评级，但顶级分析师认为这五只股票更值得买入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Microbot Medical Inc.（NASDAQ:MBOT）的空头头寸减少了 57.3%